“Last month in tweets” took a hiatus in the first quarter of 2016, but now it’s back! Why the break? The answer is Y Combinator. On January 4th, PLab was accepted into YC’s Winter 2016 batch. The all-consuming 3-month startup accelerator took precedence over basically everything, including blogging. But with Demo Day in the rearview mirror, let’s recap the goings on at PLab since the new year.
Here's a plot of body weight change for the low dose group after 8 weeks of PERL101 administered once-a-day orally. pic.twitter.com/lZKZ0Geuyo
— Perlara (@PerlaraPBC) January 6, 2016
A long overdue PERL101 update post is in the offing because we’ve made considerable progress with this lead compound for NPC. This includes a 12-week tolerability study in wildtype mice dosed daily and orally with PERL101. The above data is a snapshot of the full dataset. More to come!
— Perlara (@PerlaraPBC) January 12, 2016
PLab was featured in Popular Science in January. Every time an article comes out about PLab, rare disease advocates and patients find out about us for the first time and make contact. It’s inspiring and at the same time sobering to realize how much work needs to be done.
Retesting 105 hits from the yeast NGLY1 modifier screen. Validated hits will be tested on our CRISPR null NGLY1 fly. pic.twitter.com/yKfTUCdTu3
— Perlara (@PerlaraPBC) January 14, 2016
While our NPC lead program is nearing the mouse efficacy stage with PERL101, our NGLY1 lead program is still in the primary screening phase. In mid-January Alec and I were retesting hits from a yeast glycosylation modifier screen. In the end 25 hits were validated and advanced to NGLY1 flies for further testing.
— Perlara (@PerlaraPBC) February 12, 2016
World Rare Disease Day 2016 was last month. Throughout February, there was buzz and interest around rare diseases, including the above mathematically inspired post by Professor Melissa Wilson Sayres at ASU.
— Perlara (@PerlaraPBC) February 19, 2016
Fellow YC W16 batchmate OpenTrons stopped by PLab to demo their personalized liquid handling robot. We love working within the science startup ecosystem, which includes companies like Science Exchange, Benchling, ECL, Transcriptic and others.
— Perlara (@PerlaraPBC) February 23, 2016
Anyone who’s been following PLab since the beginning knows that we’re committed to being open. That includes being open about our finances.
— Perlara (@PerlaraPBC) February 28, 2016
Our partners in NGLY1, the Grace Science Foundation, revamped their website for Rare Disease Day 2016.
As of last week we've raised a total of $3.5M. Onward!
— Perlara (@PerlaraPBC) March 7, 2016
In the run up to Demo Day, PLab was honored and thrilled to bring on new investor Slow Ventures.
— Perlara (@PerlaraPBC) March 12, 2016
NGLY1 results hot off the presses — ngly1 mutant flies are small as adults and developmentally delayed as larvae. pic.twitter.com/frPb3W7NEm
— Perlara (@PerlaraPBC) March 18, 2016
Sangeetha took to the blog to lay out a vision for scaling PLab, and Tom and Tamy rolled out the latest results on our efforts to develop a high-throughout screen for NGLY mutant flies.
— TechCrunch (@TechCrunch) March 18, 2016
Perlstein Lab (YC W16) Automates Drug Discovery for Rare Diseases https://t.co/7F2OYzdeQs
— Y Combinator (@ycombinator) March 21, 2016
And of course the biggest news was our YC launch press. See you next month!